https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45109 n = 230 patients (mean age 65, males n = 124 (53.9%)) were treated with bevacizumab during the study period. N = 28 patients were admitted to hospital for a major cardiovascular-related event. Higher total treatment dose (p < 0.05), concomitant hypertension (p = 0.005), diabetes (p = 0.04), atrial fibrillation (p = 0.03), and lack of use of statin therapy (p = 0.03) were key contributors to hospital admission. Conclusions: Results of our study highlight the fact that patients with concomitant baseline cardiovascular disease/risk factors are at an increased risk of cardiovascular hospitalization related to bevacizumab treatment. Careful baseline cardiovascular assessment may be an essential step to minimize cardiovascular complications.]]> Wed 26 Oct 2022 13:22:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33815 Wed 19 Jan 2022 15:18:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51659 Wed 13 Sep 2023 10:02:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52531 Wed 13 Mar 2024 07:45:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36805 Tue 07 Jul 2020 10:16:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15479 Sat 24 Mar 2018 08:19:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5083 Sat 24 Mar 2018 07:48:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5055 Sat 24 Mar 2018 07:48:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4993 A/3111-1G>A. Two cases had no gastrointestinal symptoms or signs of PA. PA is an inconstant feature of the subtype of epidermolysis bullosa known as JEB-PA. It is most likely that multiple factors influence the development of PA and its presence is not predictive of a poor outcome. It is possible that institutions that do not routinely screen immunofluorescence mapping for integrin α6β4 staining in the absence of PA are missing this form of epidermolysis bullosa.]]> Sat 24 Mar 2018 07:44:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27255 Sat 24 Mar 2018 07:29:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28765 P<0.15 or if considered clinically important and readmission status. Results: Among 3328 patients, 6.5% were readmitted within 28 days (mean age, 75; 48% female; 92% ischemic). After bivariate analyses 14/43 factors from 4/5 categories were associated with readmission after hospitalization for stroke. Two factors from patient and health outcome categories remained independently associated with readmission after multivariable analyses. These were dependent premorbid functional status (adjusted odds ratio, 1.87; 95% confidence interval, 1.25–2.81) and having a severe adverse event during the initial hospitalization for stroke (adjusted odds ratio, 2.81; 95% confidence interval, 1.55–5.12). Conclusions: This is the first study to comprehensively evaluate factors associated with 28-day readmission after stroke. The factors associated with 28-day readmission are diverse and include potentially modifiable and nonmodifiable factors.]]> Sat 24 Mar 2018 07:24:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39001 P < .001), thus resulting in a median increase in costs (in Australian dollars) of $33,338 (confidence interval, $21,943-$38,415). Several baseline characteristics were strongly associated with a bleeding event. Conclusions: The impact of a bleeding event on the cost of cardiac surgery is substantial. This study identified a set of risk factors for bleeding that could be used to identify patients for discussion at the heart team level, where measures to minimize the risk of transfusion may be initiated.]]> Mon 29 Jan 2024 17:47:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41100 Mon 25 Jul 2022 10:38:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51092 Mon 21 Aug 2023 11:21:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44181 Mon 10 Oct 2022 10:48:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46522 Fri 25 Nov 2022 09:26:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48637 Fri 24 Mar 2023 13:23:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48097 Fri 24 Feb 2023 15:31:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54853 Fri 15 Mar 2024 17:15:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35053 Fri 14 Jun 2019 14:22:59 AEST ]]>